HTBX Heat Biologics Inc.

1.37
+0.02  (+1%)
Previous Close 1.35
Open 1.35
Price To Book 1.8
Market Cap 44466287
Shares 32,457,144
Volume 1,283,294
Short Ratio
Av. Daily Volume 476,360

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 interim data to be presented at 2019 ASCO-SITC February 28, 2019 1pm PST.
HS-110 and nivolumab (Opdivo)
Non-small cell lung cancer (NSCLC)
Phase 2 trial did not meet primary endpoint - November 30, 2016.
HS-410
Bladder cancer
Phase 1b data released December 6, 2016.
HS-110
Non-small cell lung cancer (NSCLC)

Latest News

  1. What Type Of Shareholder Owns Heat Biologics, Inc.’s (NASDAQ:HTBX)?
  2. UPDATE: Heat Biologics Doses First Patient in New Cohort of its Expanded Phase 2 Trial of HS-110 in Combination with Merck's KEYTRUDA(R) in Non-Small Cell Lung Cancer Trial
  3. Heat Biologics Doses First Patient in New Cohort of its Expanded Phase 2 Trial of HS-110 in Combination with Merck's KEYTRUDA(R) in Non-Small Cell Lung Cancer Trial
  4. The Daily Biotech Pulse: Cancer Genetics Prices Offering, DiaMedica Delists From Canadian Exchange, Medigus CEO Quits
  5. Heat Biologics Provides Clinical and Business Update
  6. Heat Biologics Principal Investigator Selected to Deliver Oral Presentation of New HS-110 Interim Phase 2 Data at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium
  7. Heat Biologics to Present at Biotech Showcase 2019 in California
  8. HTBX: Plenty of Catalysts in 2019
  9. Durham company rakes in another $13.8M through public offering
  10. Heat Biologics, Inc. Announces Closing of $13,800,000 Public Offering
  11. Heat Biologics to Participate in Panel Presentation at the Goldman Sachs Asia Pacific Healthcare Forum
  12. Heat Biologics Takes Beating After Pricing $12 Million Stock Offering
  13. Should You Be Concerned About Heat Biologics Inc’s (NASDAQ:HTBX) Historical Volatility?
  14. The Daily Biotech Pulse: Mylan Recalls Blood Pressure Drug, Heat Biologics Offering, New Novelion CEO
  15. Heat Biologics, Inc. Prices $12,000,000 Public Offering
  16. Heat Biologics, Inc. Announces Proposed Public Offering
  17. Heat Biologics Reports Third Quarter 2018 Results and Provides Corporate Update
  18. Heat Biologics to Present at Precision: Lung Cancer World R&D Summit
  19. Heat Biologics CEO to Participate in Panel Presentation at The Cellular ''Living Drug'' Revolution Summit in New York City